Showing 4821-4830 of 10638 results for "".
Why Clinical Skills are Crucial to Early Psoriatic Arthritis Diagnosis
https://reachmd.com/programs/beyond-skin-deep/why-clinical-skills-are-crucial-to-early-psoriatic-arthritis-diagnosis/10147/Detecting PsA isn’t easy, but these essential tips will help sharpen your screening skills so you can make an accurate AND timely diagnosis.Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
https://reachmd.com/programs/Audioabstracts/vedolizumab-induction-and-maintenance-therapy-crohns-disease-patients-naive-or-who-have-failed-tumor/9537/Vedolizumab had increased efficacy over placebo in CD patients irrespective of TNF-α antagonist treatment history.Advancing MS Care: Evolving Treatments and High-Efficacy Approaches
https://reachmd.com/programs/neurofrontiers/program-name/36356/Multiple sclerosis (MS) treatment has transformed dramatically, with a wide range of high-efficacy options currently available. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, explores how advancements in drug availability, administration methods, and efficacy are reshaping care, with aUnderstanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
https://reachmd.com/programs/Audioabstracts/understanding-safety-profiles-of-ros1-tkis-in-advanced-non-small-cell-lung-cancer/54576/Targeted therapies have transformed care for patients with ROS1-rearranged advanced non-small cell lung cancer, but long-term treatment makes safety and tolerability critical. In this AudioAbstract, Ryan Quigley breaks down a 2025 systematic review examining toxicity profiles across seven ROS1 tyrosReActivate RX Serum
https://reachmd.com/ma-issues-index/september-october-2025/reactivate-rx-serum/39277/A Multi-Technology Approach to Collagen ReactivationClinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
https://reachmd.com/programs/advances-in-womens-health/clinical-outcomes-of-radiation-vs-chemoradiation-in-recurrent-endometrial-cancer/37231/The recent NRG0238 trial evaluated whether adding chemotherapy to radiation improves outcomes in patients with localized endometrial cancer recurrences. Hear from Dr. Ann Klopp as she explains the findings and how they could shift practice patterns for patient care. Dr. Klopp is a Professor of RadiaColorectal Cancer Screening: Evaluating the Cost-Effectiveness of Noninvasive Options
https://reachmd.com/programs/clinicians-roundtable/colorectal-cancer-screening-evaluating-the-cost-effectiveness-of-noninvasive-options/33058/Colorectal cancer screening strategies have significantly evolved in recent years, with noninvasive options like stool and blood-based tests explored for their potential to boost adherence. Drs. Gloria Coronado and Carolyn Rutter join Dr. Brian McDonough to evaluate how these methods compare to tradFrom Pathophysiology to Therapeutic Progress: TYK2's Significance in Plaque Psoriasis
https://reachmd.com/programs/spotlight-psoriasis/from-pathophysiology-to-therapeutic-progress-tyk2s-significance-in-plaque-psoriasis/15835/How can our understanding of TYK2 help us better treat our patients with moderate-to-severe plaque psoriasis? Join us to find out.Bottles of Lies: The Inside Story of the Generic Drug Boom
https://reachmd.com/programs/book-club/bottles-lies-inside-story-generic-drug-boom/10887/We’ve all heard that generic drugs are equal to brand-name ones in all areas except for their low price. But is this true?Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
https://reachmd.com/clinical-practice/nephrology/optimizing-igan-care-sparsentans-role-amid-the-latest-kdigo-guideline-updates/30044/Examine updated KDIGO 2025 IgAN guidelines and sparsentan’s role in managing proteinuria and slowing kidney function decline.